Clinical Trials | December 17, 2024
Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
For people with relapsed or refractory diffuse large B-cell lymphoma
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The inspection concluded with the issuance of a form 483 with five observations
Subscribe To Our Newsletter & Stay Updated
